Literature DB >> 18489850

Off-target toxicity: risks associated with adrenal corticoid activation in ILLUMINATE.

Robert S Rosenson.   

Abstract

Entities:  

Year:  2008        PMID： 18489850     DOI： 10.1007/s11883-008-0035-x

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  11 in total

1.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Authors:  Philip Barter; Antonio M Gotto; John C LaRosa; Jaman Maroni; Michael Szarek; Scott M Grundy; John J P Kastelein; Vera Bittner; Jean-Charles Fruchart
Journal:  N Engl J Med       Date:  2007-09-27       Impact factor: 91.245

2.  Eplerenone inhibits atherosclerosis in nonhuman primates.

Authors:  Shinji Takai; Denan Jin; Michiko Muramatsu; Kazuyoshi Kirimura; Hiroshi Sakonjo; Mizuo Miyazaki
Journal:  Hypertension       Date:  2005-10-03       Impact factor: 10.190

3.  Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.

Authors:  Robert S Rosenson
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

4.  Mineralocorticoid receptor antagonism in experimental atherosclerosis.

Authors:  Sanjay Rajagopalan; Damon Duquaine; Steven King; Bertram Pitt; Paresh Patel
Journal:  Circulation       Date:  2002-05-07       Impact factor: 29.690

5.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.

Authors:  Michael H Davidson; James M McKenney; Charles L Shear; James H Revkin
Journal:  J Am Coll Cardiol       Date:  2006-11-07       Impact factor: 24.094

6.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.

Authors:  James M McKenney; Michael H Davidson; Charles L Shear; James H Revkin
Journal:  J Am Coll Cardiol       Date:  2006-11-07       Impact factor: 24.094

7.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.

Authors:  Shlomo Keidar; Marielle Kaplan; Elsa Pavlotzky; Raymond Coleman; Tony Hayek; Shadi Hamoud; Michael Aviram
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

10.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.